(ACTH) for the Treatment of Sarcoid Uveitis

Status unconfirmed

Conditions studied: Sarcoid Uveitis

In brief

Sarcoidosis is a multisystem granulomatous disease that can affect nearly any organ in the body. While most commonly affecting the lungs, vision threatening eye involvement occurs in approximately 25% of patients with sarcoid. Eye involvement may lead to a chronic, sight-threatening uveitis which may result in cataract, glaucoma, and macular edema. The treatment of sarcoid uveitis involves the use of topical and systemic corticosteroids or potent immunosuppressive agents (medications that suppress the body's immune system) both of which can cause severe long-term side effects. The adverse effects of steroids may be avoided by treatment with the use as H.P. Acthar® Gel. The effectiveness of H.P. Acthar® Gel in the treatment of sarcoid uveitis and patient quality of live have not been previously examined. These issues, will be explored in this research.

Key facts

Study ID

NCT03473964

Run by

John Huang, MD

People needed

10

Starts

2018-04-01

Expected to finish

2020-01-01

Last updated by the study team

2018-03-22

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Presence of Sarcoid Uveitis as determined by
• clinical exam
• fluorescence angiography
• optical coherence tomography

You may not qualify if…

• Presence of long acting intraocular depots
• Women of childbearing age not using contraceptives

Where it is running

• New England Retina Associates — Hamden, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.